Schultze-Mosgau MH - Search Results

1

Cytochrome P450 dependent N-hydroxylation of a guanidine (debrisoquine), microsomal catalysed reduction and further oxidation of the N-hydroxy-guanidine metabolite to the urea derivative. Similarity with the oxidation of arginine to citrulline and nitric oxide.

Clement B, Schultze-Mosgau MH, Wohlers H. Clement B, et al. Biochem Pharmacol. 1993 Dec 14;46(12):2249-67. doi: 10.1016/0006-2952(93)90616-5. Biochem Pharmacol. 1993. PMID: 8274159

2

Cytochrome P450-dependent N-hydroxylation of an aminoguanidine (amidinohydrazone) and microsomal retroreduction of the N-hydroxylated product.

Clement B, Schultze-Mosgau MH, Richter PH, Besch A. Clement B, et al. Xenobiotica. 1994 Jul;24(7):671-88. doi: 10.3109/00498259409043269. Xenobiotica. 1994. PMID: 7975731

3

Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.

Chattopadhyay N, Riecke K, Ligges S, Zimmermann T, Halabi A, Schultze-Mosgau MH. Chattopadhyay N, et al. Among authors: schultze mosgau mh. Br J Clin Pharmacol. 2019 Sep;85(9):2011-2021. doi: 10.1111/bcp.13992. Epub 2019 Jul 10. Br J Clin Pharmacol. 2019. PMID: 31112623 Free PMC article. Clinical Trial.

4

The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive-A randomized controlled trial.

Schultze-Mosgau MH, Schütt B, Draeger C, Casjens M, Loewen S, Zimmermann T, Rohde B. Schultze-Mosgau MH, et al. Br J Clin Pharmacol. 2021 Mar;87(3):925-936. doi: 10.1111/bcp.14443. Epub 2020 Jul 24. Br J Clin Pharmacol. 2021. PMID: 32592596 Free PMC article. Clinical Trial.

5

Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment.

Schultze-Mosgau MH, Lasseter KC, Marbury T, Loewen S, Riecke K. Schultze-Mosgau MH, et al. J Clin Pharmacol. 2020 Aug;60(8):1030-1038. doi: 10.1002/jcph.1608. Epub 2020 Mar 30. J Clin Pharmacol. 2020. PMID: 32227643 Free PMC article. Clinical Trial.

6

Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women.

Liu H, Jiang J, Chen Z, Zhang Y, Li J, Hoechel J, Rohde B, Zimmermann T, Schultze-Mosgau MH. Liu H, et al. Among authors: schultze mosgau mh. Clin Pharmacol Drug Dev. 2021 May;10(5):486-493. doi: 10.1002/cpdd.851. Epub 2020 Jul 27. Clin Pharmacol Drug Dev. 2021. PMID: 32716091 Free PMC article. Clinical Trial.

7

Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women.

Schultze-Mosgau MH, Kaiser A, Zollmann FS. Schultze-Mosgau MH, et al. Clin Pharmacol Drug Dev. 2021 Jun;10(6):675-680. doi: 10.1002/cpdd.876. Epub 2020 Oct 5. Clin Pharmacol Drug Dev. 2021. PMID: 33021044 Free PMC article. Clinical Trial.

8

Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation.

Sutter G, Frei M, Schultze-Mosgau MH, Petersdorf K, Seitz C, Ploeger BA. Sutter G, et al. Among authors: schultze mosgau mh. Br J Clin Pharmacol. 2022 Feb;88(2):734-741. doi: 10.1111/bcp.15014. Epub 2021 Aug 25. Br J Clin Pharmacol. 2022. PMID: 34327754 Free PMC article.

9

Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview.

Schultze-Mosgau MH, Ploeger BA, Frei M, Höchel J, Rottmann A. Schultze-Mosgau MH, et al. Clin Pharmacokinet. 2022 Jan;61(1):1-16. doi: 10.1007/s40262-021-01073-3. Epub 2021 Sep 27. Clin Pharmacokinet. 2022. PMID: 34569009 Free PMC article. Review.

10

Single- and Multiple-Dose Pharmacokinetics and Safety of Vilaprisan in Healthy Postmenopausal Japanese Women: A Randomized Clinical Trial.

Schultze-Mosgau MH, Matsuki S, Okumura K, Kaneko M. Schultze-Mosgau MH, et al. Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):49-56. doi: 10.1007/s13318-021-00727-8. Epub 2021 Oct 11. Eur J Drug Metab Pharmacokinet. 2022. PMID: 34635989 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page